Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
29.86
+0.52 (1.77%)
At close: Aug 29, 2025, 4:00 PM
29.79
-0.07 (-0.23%)
After-hours: Aug 29, 2025, 7:18 PM EDT
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.18M in the quarter ending June 30, 2025, a decrease of -52.42%. This brings the company's revenue in the last twelve months to $74.93M, down -19.56% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$74.93M
Revenue Growth
-19.56%
P/S Ratio
5.59
Revenue / Employee
$1,228,426
Employees
61
Market Cap
567.89M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NKTR News
- 22 days ago - Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Nektar Therapeutics Reports Second Quarter 2025 Financial Results - PRNewsWire
- 4 weeks ago - Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 4 weeks ago - Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces Pricing of $100 Million Public Offering - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces Proposed Public Offering - PRNewsWire
- 2 months ago - Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg - Seeking Alpha